Stock Ratings / Health Care / RCUS / insiders

HCM (46) PGEN (35) PHVS (63) PBH (72) ⌘ Pro Terminal →

Arcus Biosciences Inc. (RCUS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Is RCUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Arcus Biosciences Inc. (NYSE: RCUS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $18.61 (+1.20% 1D, market cap $2.37B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RCUS ranks #809 in composite RQD confidence.

Q: How does RCUS compare to HCM and PGEN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RCUS carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HCM (HUTCHMED (China) Limited) holds a D grade (46/100 RQD, P/E 5.2x, ROIC -2.5%, cap $2.37B) and PGEN (Precigen Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.38B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for RCUS?

Per RCUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001724521), Arcus Biosciences Inc. generated $33.0M in revenue (-35.3% YoY), -$353.0M in net income, and -$484.0M in free cash flow against $1.14B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is RCUS trading relative to its 50-day, 200-day, and 52-week technical levels?

RCUS last traded at $18.61 (+1.20% on volume of 1,665,799 shares), positioning the stock -25.50% below its 50-day simple moving average ($24.98) and -24.53% below its 200-day simple moving average ($24.66). Across its 52-week range of $17.43 to $31.74, RCUS sits at the 8.2% percentile with a 14-day RSI of 30.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($16.28 to $20.94).

Q: Are RCUS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies RCUS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$18.61 +1.20% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $18.61

Arcus Biosciences Inc. (RCUS) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $2.37B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $18.62 (+0.03%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RCUS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY RCUS SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (37% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 30 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$24.41-9.4% Next Q

Q2 (-2Q)

Grade D$22.12-16.2% Next Q

Q3 (-1Q)

Grade E$18.54+0.4% Next Q

Current

Grade D-$18.61-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RCUS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RCUS currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.98) and Max Pain ($19.54) forces dealer call-delta covering toward $33.33.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RCUS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RCUS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

RCUS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (RCUS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on RCUS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RCUS)

✓Walkthrough of RCUS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RCUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.02%📐 HORIZONTAL RANGE

2026-10-30O $18.34H $18.90L $17.81C $18.61VOL 1.94M

RES: $31.39SUP: $16.70SMA50: $24.98SMA200: $24.66

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RCUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RCUS Butterfly Map → + Track RCUS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -35.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RCUS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RCUS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RCUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RCUS)

Health Care Rank #809 of 1016 ⚔️ HCM vs RCUS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RCUS vs. HCM, PGEN, PHVS, PBH)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Arcus Biosciences Inc. (RCUS) ranks #809 by composite RQD confidence (35/100, grade D-) and #229 by equity capitalization ($2.37B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while PBH leads on capital efficiency and profitability with 13.8% ROIC and 54.7% gross margin. PBH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with RCUS at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RCUS ACTIVE Arcus Biosciences Inc.	D-	35/100	—	—	-35.0%	+1.20%	$2.37B	Benchmark Subject
HCM HUTCHMED (China) Limited	D	46/100	5.2x	—	-2.5%	+2.03%	$2.37B	/hcm-vs-rcus →
PGEN Precigen Inc.	D-	35/100	—	—	-35.0%	+9.21%	$2.38B	/pgen-vs-rcus →
PHVS Pharvaris N.V.	C	63/100	—	—	—	+2.32%	$2.34B	/phvs-vs-rcus →
PBH Prestige Consumer Healthcare Inc.	B	72/100	12.1x	54.7%	13.8%	+2.01%	$2.31B	/pbh-vs-rcus →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001724521

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Arcus Biosciences Inc. (RCUS) reported GAAP revenue of $33.0M (-35.3% vs. FY2024 revenue of $51.0M , and -10.8% cumulative change since FY2023) , GAAP net income of -$353.0M, operating cash flow of -$482.0M, and free cash flow of -$484.0M (-175.0% YoY). On the balance sheet, RCUS closed FY2025 with $1.14B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$33.0M	-$353.0M	-$482.0M	-$484.0M	$1.14B	—
FY2024 (FY)	2024-12-31	$51.0M	-$283.0M	-$170.0M	-$176.0M	$1.15B	—
FY2023 (FY)	2023-12-31	$37.0M	-$307.0M	-$306.0M	-$306.0M	—	—

3. RCUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RCUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Arcus Biosciences Inc. (NYSE: RCUS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $18.61 (+1.20% 1D, market cap $2.37B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RCUS ranks #809 in composite RQD confidence.

How does RCUS compare to HCM and PGEN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RCUS carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HCM (HUTCHMED (China) Limited) holds a D grade (46/100 RQD, P/E 5.2x, ROIC -2.5%, cap $2.37B) and PGEN (Precigen Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.38B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RCUS?

Per RCUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001724521), Arcus Biosciences Inc. generated $33.0M in revenue (-35.3% YoY), -$353.0M in net income, and -$484.0M in free cash flow against $1.14B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RCUS trading relative to its 50-day, 200-day, and 52-week technical levels?

RCUS last traded at $18.61 (+1.20% on volume of 1,665,799 shares), positioning the stock -25.50% below its 50-day simple moving average ($24.98) and -24.53% below its 200-day simple moving average ($24.66). Across its 52-week range of $17.43 to $31.74, RCUS sits at the 8.2% percentile with a 14-day RSI of 30.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($16.28 to $20.94).

RCUS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are RCUS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies RCUS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: RCUS RQD Cockpit RCUS 12M Forecast RCUS Earnings & Move RCUS Dividends & DRIP RCUS Insiders & 13F RCUS Whale Options RCUS Profit Sankey RCUS News & Why